Updated: Sep 19, 2021
COVID-19 Miracle Cure: Scientists Say Ivermectin, An Anti-Parasitic Drug, Could Be The Answer To Ending Pandemic
A peer review has claimed that global use of ivermectin can end the COVID-19 pandemic, as it considerably reduces the risk of developing fatal respiratory disease regularly. The common anti-parasitic ivermectin is being promoted by doctors and campaigners worldwide as a miracle cure for COVID-19. This study was evaluated by medical experts, including three senior US government scientists, and the most comprehensive review of data available from clinical, in vitro, animal, and real-world studies. It is published in the US Journal.
During a review of published peer review studies, manuscripts, meta-analysis experts and epidemiological tests in regions with ivermectin distribution efforts, led by the Front Line COVID-19 Critical Care Alliance (FLCCC), a group of medical and scientific experts showed that ivermectin is effective prophylaxis- and treatment of COVID-19.
They did the work that the medical authorities failed to do, according to the researchers. The most comprehensive examination has been done on the available data on ivermectin and the gold standard has been used to qualify the reviewed data before ivermectin can end the pandemic. The manuscript focused on 27 controlled tests, 15 of which were randomized controlled trials (RCT’s), available in January 2021. Most regions worldwide now recognize the strong prophylaxis and treatment of Covid-19 with ivermectin.
ivermectin approved for use in India as well
The drug has been approved for use by medical professionals in South Africa, Zimbabwe, Slovakia, the Czech Republic, Mexico, and India. The results of this last study show that the distribution campaigns for ivermectin repeatedly led to “rapid decreases in morbidity and mortality across the entire population.” Researchers called on regional public health authorities and physicians worldwide to demand that ivermectin be incorporated immediately in their standard of care so that we can end this pandemic once and for all.
according to the researchers, patients with persistent Covid-19 symptoms who completed a six-week supervised rehabilitation program demonstrated significant improvements in exercise capacity, respiratory symptoms, fatigue, and cognition, including one of Indian ancestry. The study discovered a statistically significant increase in exercise capacity, as measured by distance traveled and the ability to continue walking without stopping, using incremental and endurance shuttle-walking tests.
Additionally, as measured by standardized clinical assessment tools, participants demonstrated improvements in their overall wellbeing and cognition. The small but significant study, published in the journal Chronic Respiratory Disease, followed thirty patients who participated in twice-weekly face-to-face exercise rehabilitation classes.
For river blindness (onchocerciasis) and lymphatic filariasis, ivermectin is typically given as part of mass drug administration campaigns that distribute the drug to all members of a community affected by the disease. For river blindness, a single oral dose of ivermectin (150 micrograms per kilogram of body weight) clears the body of larval Onchocerca volvulus worms for several months, preventing transmission and disease progression. Adult worms survive in the skin and eventually recover to produce larval worms again. To keep the worms at bay, ivermectin is given at least once per year for the 10–15-year lifespan of the adult worms. For lymphatic filariasis, oral ivermectin (200 micrograms per kilogram body weight) is part of a combination treatment given annually: ivermectin, diethylcarbamazine citrate, and albendazole in places without onchocerciasis; ivermectin and albendazole in places with onchocerciasis.[note 1]
The World Health Organization (WHO) considers ivermectin the "drug of choice" for strongyloidiasis. Most cases are treated with two daily doses of oral ivermectin (200 μg per kg body weight), while severe infections are treated with five to seven days of ivermectin. Ivermectin is also the primary treatment for Mansonella Rizzardi and cutaneous larva migrans. The U.S. Centers for Disease Control and Prevention (CDC) recommends ivermectin, albendazole, or mebendazole as treatments for ascariasis.[note 2] Ivermectin is sometimes added to albendazole or mebendazole for whipworm treatment and is considered a second-line treatment for gnathostomiasis.
Mites and insects
Ivermectin is also used to treat infection with parasitic arthropods. Scabies – infestation with the mite Sarcoptes scabiei – is most commonly treated with topical permethrin or oral ivermectin. For most scabies cases, ivermectin is used in a two-dose regimen: a first dose kills the active mites, but not their eggs. Over the next week, the eggs hatch, and a second dose kills the newly hatched mites. For severe "crusted scabies", the U.S. Centers for Disease Control and Prevention (CDC) recommends up to seven doses of ivermectin over a month, along with a topical antiparasitic. Both head lice and pubic lice can be treated with oral ivermectin, a 0.5% ivermectin lotion applied directly to the affected area or various other insecticides. Ivermectin is also used to treat rosacea and blepharitis, both of which can be caused or exacerbated by Demodex folliculorum mites.
Mechanism of action
Ivermectin and its related drugs act by interfering with the nerve and muscle function of helminths and insects. The drug binds to glutamate-gated chloride channels that are common to invertebrate nerve and muscle cells. Ivermectin binding pushes these channels open, increasing the flow of chloride ions and hyper-polarizing the cell membranes. This hyperpolarization paralyzes the affected tissue, eventually killing the invertebrate. In mammals, ivermectin cannot cross the blood-brain barrier and so it does not make it to the brain.
Ivermectin can be given by mouth, topically, or via injection. It does not readily cross the blood-brain barrier of mammals due to the presence of P-glycoprotein (the MDR1 gene mutation affects the function of this protein). Crossing may still become significant if ivermectin is given at high doses (in which case, brain levels peak 2–5 hours after administration). In contrast to mammals, ivermectin can cross the blood-brain barrier in tortoises, often with fatal consequences.
Field studies have demonstrated the dung of animals treated with ivermectin supports a significantly reduced diversity of invertebrates, and the dung persists longer.
Credited to new jersey times